Idecabtagene Vicleucel (Abecma)

Type: gene_therapy

Status: FDA Approved

Developer: Bristol Myers Squibb and bluebird bio

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026